<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843475</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-04-15</org_study_id>
    <nct_id>NCT04843475</nct_id>
  </id_info>
  <brief_title>Study of Pulmonary Hypertension in Patients With Chronic Myeloproliferative Disorders at Sohag University Hospital</brief_title>
  <official_title>Study of Pulmonary Hypertension in Patients With Chronic Myeloproliferative Disorders at Sohag University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension (PH) is a complex condition that may be related to many clinical&#xD;
      conditions. It is a serious disorder with a high morbidity and mortality rates. PH is&#xD;
      classified into five groups according to clinical characteristics, pathological findings,&#xD;
      hemodynamic characteristics and treatment response (Galie N, et al., 2016). These five groups&#xD;
      include pulmonary arterial hypertension, PH due to left sided heart disease, PH due to lung&#xD;
      disease and/or hypoxia, chronic thromboembolic pulmonary hypertension, or other pulmonary&#xD;
      arterial obstruction and PH with unclear and/or multifactorial mechanisms (Simonneau G, et&#xD;
      al., 2013).&#xD;
&#xD;
      PH is a major complication of several hematologic disorders including myeloproliferative&#xD;
      neoplasms (MPNs). MPNs are a group of diseases characterized by uncontrolled proliferation of&#xD;
      at least one myeloid series due to an abnormal hematopoietic cell clone. There are different&#xD;
      types of MPNs including polycythemia vera (PV), essential thrombocythemia (ET), primary&#xD;
      myelofibrosis (PMF) &amp; chronic myeloid leukemia ( CML). Myeloproliferative neoplasms (MPNs)&#xD;
      are included in group 5 PH (Arber DA, et al., 2016).&#xD;
&#xD;
      This study will analyze the clinical and laboratory data of MPNs patients and correlate them&#xD;
      with development of PH in these patients aiming to identify parameters that can predict PH in&#xD;
      MPNs patients and thus, identifying MPNs patients at highest risk for PH who require close&#xD;
      monitoring &amp; screening for PH hoping that early detection and management of PH in MPNs&#xD;
      patients can improve morbidity, prognosis and survival in those patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of pulmonary hypertension in chronic myeloproliferative disorders patients</measure>
    <time_frame>2 years</time_frame>
    <description>Prevalence of pulmonary hypertension in chronic myeloproliferative disorders patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of independent different predictors of pulmonary hypertension in chronic myeloproliferative disorders patients</measure>
    <time_frame>2 years</time_frame>
    <description>Identification of independent different predictors of pulmonary hypertension in chronic myeloproliferative disorders patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>MPNs patients who have echocardiographic probability of PH.</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MPNs patients who do not have echocardiographic probability of PH</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Trans-thoracic Echocardiography</description>
    <arm_group_label>MPNs patients who do not have echocardiographic probability of PH</arm_group_label>
    <arm_group_label>MPNs patients who have echocardiographic probability of PH.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The outpatient Hematology Clinic at Sohag University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old.&#xD;
&#xD;
          -  Patients diagnosed with polycythemia vera, essential thrombocythemia, primary&#xD;
             myelofibrosis and chronic myeloid leukemia according to the 2016 WHO classification&#xD;
             and attended the outpatient Hematology Clinic at Sohag University Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 18 years old.&#xD;
&#xD;
          -  Patients with pre-existing pulmonary hypertension from any other cause.&#xD;
&#xD;
          -  Patients with left sided heart disease e.g. left sided heart failure, left sided&#xD;
             valvular diseases, cardiomyopathies, left ventricular systolic or diastolic&#xD;
             dysfunction.&#xD;
&#xD;
          -  Patients with chronic lung disease e.g. COPD &amp; interstitial lung disease.&#xD;
&#xD;
          -  Patients with chronic kidney disease.&#xD;
&#xD;
          -  Patients with connective tissue diseases.&#xD;
&#xD;
          -  Patients with congenital heart diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mahmoud H Ahmed, Master</last_name>
    <phone>01003707775</phone>
    <email>mahmoudhamdy@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ali M Kassem, Professor</last_name>
    <phone>01003459738</phone>
  </overall_contact_backup>
  <reference>
    <citation>Gali√® N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.</citation>
    <PMID>26320113</PMID>
  </reference>
  <reference>
    <citation>Yaylali YT, Yilmaz S, Akgun-Cagliyan G, Kilic O, Kaya E, Senol H, Ozen F. Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm. Med Princ Pract. 2020;29(5):486-491. doi: 10.1159/000506596. Epub 2020 Feb 19.</citation>
    <PMID>32069470</PMID>
  </reference>
  <reference>
    <citation>Lopez-Mattei J, Verstovsek S, Fellman B, Iliescu C, Bhatti K, Hassan SA, Kim P, Gray BA, Palaskas NL, Grosu HB, Mamas MA, Faiz SA. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2020 Apr;99(4):781-789. doi: 10.1007/s00277-020-03962-2. Epub 2020 Feb 19.</citation>
    <PMID>32076825</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Mahmoud Hamdy Ahmed</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

